lentiviral-mediated COL7A1 gene-modified autologous fibroblasts (Kings College London/University College London)

N/A

Report date: 2025/02/25 11:46:39

Base Information

Drug Namelentiviral-mediated COL7A1 gene-modified autologous fibroblasts (Kings College London/University College London)
Drug Alias NameCOL7A1 gene-modified autologous fibroblasts (KCL/UCL)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCOL7A1 gene transference
TargetsCollagen alpha-1(VII) chain
Therapy Area/IndicationsEpidermolysis Bullosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKing'S College London
China Registration ClassN/A

Develop Information

Active CompaniesUniversity College LondonKing'S College London
Inactive CompaniesN/A
Active IndicationsEpidermolysis Bullosa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A